Sanofi rolls out PhII mul­ti­ple scle­ro­sis da­ta that will take the phar­ma in­to piv­otal stud­ies next year

While one of its main bets on mul­ti­ple scle­ro­sis is stuck in a year-long par­tial clin­i­cal hold, Sanofi has new mid-stage da­ta on an­oth­er in­ves­ti­ga­tion­al MS ther­a­py that the com­pa­ny says lay the ground­work for piv­otal tri­als next year.

On Wednes­day, the French phar­ma said its in­ves­ti­ga­tion­al drug frex­al­imab was bet­ter than place­bo at re­duc­ing cer­tain types of brain le­sions as ob­served by MRI at week 12. The study in­clud­ed 129 peo­ple with re­laps­ing mul­ti­ple scle­ro­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER